Guidelines for managing diabetes in Ramadan

Diabetic Medicine

Volumn 33, Issue 10, 2016, Pages 1315-1329

  Ali, S ^a   Davies, M J ^b,c   Brady, E M ^c   Gray, L J ^d   Khunti, K ^b,c   Beshyah, S A ^e   Hanif, W ^f  

^a IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

^b UNIVERSITY OF LEICESTER   (United Kingdom)

^c UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST   (United Kingdom)

^d UNIVERSITY OF LEICESTER   (United Kingdom)

^e SHEIKH KHALIFA MEDICAL CITY   (United Arab Emirates)

^f UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; CANAGLIFLOZIN; DAPAGLIFLOZIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLUCAGON LIKE PEPTIDE RECEPTOR AGONIST; GLUCOSE; HUMAN INSULIN; INSULIN; INSULIN ASPART; INSULIN GLARGINE; INSULIN LISPRO; ISOPHANE INSULIN; LIRAGLUTIDE; LIXISENATIDE; LONG ACTING INSULIN; METFORMIN; NATEGLINIDE; PIOGLITAZONE; PLACEBO; RECOMBINANT HUMAN INSULIN; REPAGLINIDE; SHORT ACTING INSULIN; SITAGLIPTIN; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; SULFONYLUREA; VILDAGLIPTIN;

BLOOD GLUCOSE MONITORING; CLINICAL TRIAL (TOPIC); DEHYDRATION; DIABETES EDUCATION; DIABETES MELLITUS; DIABETIC DIET; DIABETIC KETOACIDOSIS; DIET RESTRICTION; EVIDENCE BASED PRACTICE; GLUCOSE ABSORPTION; GLUCOSE BLOOD LEVEL; HIGH RISK PATIENT; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN PUMP; INSULIN RELEASE; INTERMEDIATE RISK PATIENT; ISLAM; LIFESTYLE MODIFICATION; LOW RISK PATIENT; MEDICAL ASSESSMENT; MULTICENTER STUDY (TOPIC); NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT EDUCATION; PHYSICAL ACTIVITY; PRACTICE GUIDELINE; PREGNANCY; RAMADAN; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; RISK FACTOR; SMOKING; THROMBOSIS;

EID: 84987842197     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/dme.13080     Document Type: Review

References (50)

1. Pew Research Center's Forum on Religion & Public Life. Available at http://www.pewforum.org/2012/12/18/global-religious-landscape-exec/ Last accessed 24 February 2014.
2. International Diabetes Federation (IDF). IDF Diabetes Atlas, 6th ed. Brussels: IDF, 2013. Available at www.idf.org/diabetesatlas Last accessed 24 February 2014.
3. Holman N, Forouhi N, Goyder E, Wild SH. The Association of Public Health Observatories (APHO) Diabetes Prevalence Model: estimates of total diabetes prevalence for England 2010–2030. Diabet Med 2011; 28: 575–582.
4. Rogers S.Muslim populations by country: how big will each Muslim population be by 2030. The Guardian, 2011. Available at www.guardian.co.uk/news/datablog/2011/jan/28/muslim-population-country-projection-2030 Last accessed 24 February 2014.
5. Pew Research Center's Forum on Religion & Public Life. Available at http://www.pewforum.org/2012/12/18/global-religious-landscape-exec/ Last accessed 24 February 2014.
6. Salti I, Be'nard E, Detournay B, Bianchi-Biscay M, Le Brigand C, Voinet C et al. Results of the Epidemiology of Diabetes and Ramadan 1422/2001 (EPIDIAR) study. Diabetes Care 2004; 27: 2306–2311.
7. Al-Arouj M, Assaad-Khalil S, Buse J, Fahdil I, Fahmy M, Hafez S et al. Recommendations for management of diabetes during Ramadan: update 2010. Diabetes Care 2010; 33: 1895–1902.
8. Hui E, Bravis V, Hassanein M, Hanif W, Malik R, Chowdhury TA et al. Management of people with diabetes wanting to fast during Ramadan. BMJ 2010; 340: 1407–1411.
9. Karamat MA, Syed A, Hanif W. Review of diabetes management and guidelines during Ramadan. J R Soc Med 2010; 103: 139–147.
10. Hassanein M, Abdallah K, Schweizer A. A double-blind, randomized trial, including frequent patient–physician contacts and Ramadan-focused advice, assessing vildagliptin and gliclazide in patients with type 2 diabetes fasting during Ramadan: the STEADFAST study. Vasc Health Risk Manag 2014; 10: 319–326.
11. Brady EM, Davies MJ, Gray LJ, Saeed MA, Smith D, Hanif W et al. A randomized controlled trial comparing the GLP–1 receptor agonist liraglutide to a sulphonylurea as add on to metformin in patients with established type 2 diabetes during Ramadan: the Treat 4 Ramadan Trial. Diabetes Obes Metab 2014; 16: 527–536.
12. Hassanein M, Hanif W, Malik W, Kamal A, Geransar P, Lister N et al. Comparison of the dipeptidyl peptidase–4 inhibitor vildagliptin and the sulphonylurea gliclazide in combination with metformin, in Muslim patients with type 2 diabetes mellitus fasting during Ramadan: results of the VECTOR study. Curr Med Res Opin 2011; 27: 1367–1374.
13. Al-Arouj M, Hassoun AA, Medlej R, Pathan MF, Shaltout I, Chawla MS et al. The effect of vildagliptin relative to sulphonylureas in Muslim patients with type 2 diabetes fasting during Ramadan: the VIRTUE study. Int J Clin Pract 2013; 67: 957–963.
14. Beshyah SA. Fasting during the month of Ramadan for people with diabetes: medicine and Fiqh united at last. Ibnosina J Med Biomed Sci 2009; 1: 58–60.
15. Bakiner O, Ertorer ME, Bozkirli E, Tutuncu NB, Demirag NG. Repaglinide plus single-dose insulin glargine: a safe regimen for low-risk type 2 diabetic patients who insist on fasting in Ramadan. Acta Diabetol 2009; 46: 63–65.
16. Elmehdawi R, Ehmida M, Elmagrehi H. Incidence of diabetic ketoacidosis during Ramadan fasting in Benghazi-Libya. Oman Med J 2009; 24: 99–102.
17. Salim I, Al Suwaidi J, Ghadban W, Alkilani H, Salam AM. Impact of religious Ramadan fasting on cardiovascular disease: a systematic review of the literature. Curr Med Res Opin 2013; 29: 343–354.
18. Saadatnia M, Zare M, Fatehi F, Ahmadi A. The effect of fasting on cerebral venous and dural sinus thrombosis. Neurol Res 2009; 31: 794–798.
19. Temizhan A, Dönderici O, Ouz D, Demirbas B. Is there any effect of Ramadan fasting on acute coronary heart disease events? Int J Cardiol 1999; 70: 149–153.
20. Davies MJ, Heller S, Skinner TC, Campbell MJ, Carey ME, Cradock S et al.; Diabetes Education and Self Management for Ongoing and Newly Diagnosed Collaborative. Effectiveness of the diabetes education and self management for ongoing and newly diagnosed (DESMOND) programme for people with newly diagnosed type 2 diabetes: cluster randomised controlled trial. BMJ 2008; 336: 491–495.
21. Bravis V, Hui E, Salih S, Mehar S, Hassanein M, Devendra D. Ramadan education and awareness in diabetes programme for Muslims with type 2 diabetes who fast during Ramadan. Diabet Med 2010; 27: 327–331.
22. Daly H, Byrne J, Martin-Stacey L, Mandalia P, Carey ME, Hadjiconstantinou M et al. ‘A safer Ramadan’: developing an integrated approach to support safer fasting and feasting for people with type 2 diabetes. Pract Diabetes 2014; 31: 292–297.
23. Muslim Council of Britain Diabetes Advisory Group (Dr Sarah Ali, Dr Sufyan Hussain, Dr Tahseen Chowdhury, Professor Wasim Hanif and Dr Shuja Shafi) and Diabetes UK. Factsheet about Ramadan and Diabetes, 2014. Available at http://www.mcb.org.uk/wp-content/uploads/2014/06/Ramadan-and-diabetes-A-guide-for-patients-2013.pdf Last accessed 23 April 2015.
24. Muslim Spiritual Care Division in the NHS. A project of the Muslim Council in Partnership with the Department of Health. Ramadan Health Factsheet 2009. Available at http://www.bcf.nhs.uk/docs/9109_8575754813.pdf Last accessed 1 February 2014.
25. Amiel SA, Dixon T, Mann R, Jameson K. Hypoglycaemia in type 2 diabetes. Diabet Med 2008; 25: 245–254.
26. Aadil N, Houti IE, Moussamih S. Drug intake during Ramadan. BMJ 2004; 329: 778–782.
27. Mucha GT, Merkel S, Thomas W, Bantle JP. Fasting and insulin glargine in individuals with type 1 diabetes. Diabetes Care 2004; 27: 1209–1210.
28. Azar ST, Khairallah WG, Merheb MT, Zantout MA, Fliti F. Insulin therapy during Ramadan fast for patients with type 1 diabetes mellitus. J Med Liban 2008; 56: 46.
29. Kadiri A, Al-Nakhi A, El-Ghazali S, Jabbar A, Al-Arouj M, Akram J et al. Treatment of type 1 diabetes with insulin lispro during Ramadan. Diabetes Metab 2001; 27: 482–486.
30. Benbarka MM, Khalil AB, Beshyah SA, MArjei S, Awad SA. Insulin pump therapy in Moslem patients with type 1 diabetes during Ramadan fasting: an observational report. Diabetes Technol Ther 2010; 12: 287–290.
31. Pan C, Yang W, Barona JP, Wang Y, Niggli M, Mohideen P et al. Comparison of vildagliptin and acarbose monotherapy in patients with type 2 diabetes: a 24–week, double-blind, randomized trial. Diabet Med 2008; 25: 435–441.
32. McIntosh B, Cameron C, Singh SR, Yu C, Ahuja T, Welton NJ et al. Second-line therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a systematic review and mixed-treatment comparison meta-analysis. Open Med 2011; 5: e35–e48.
33. Mafauzy M. Repaglinide versus glibenclamide treatment of type 2 diabetes during Ramadan fasting. Diabetes Res Clin Pract 2002; 58: 45–53.
34. Sari R, Balci MK, Akbas SH, Avci B. The effects of diet, sulfonylurea and repaglinide therapy on clinical and metabolic parameters in type 2 diabetic patients during Ramadan. Endocr Res 2004; 30: 169–177.
35. Anwar A, Azmi KN, Hamidon BB, Khalid BA. An open label comparative study of glimepiride versus repaglinide in type 2 diabetes mellitus Muslim subjects during the month of Ramadan. Med J Malaysia 2006; 61: 28–35.
36. Glimperide in Ramadan (GLIRA) Study Group. The efficacy and safety of glimepiride in the management of type 2 diabetes in Muslim patients during Ramadan. Diabetes Care 2005; 28: 421–422.
37. Vasan S, Thomas N, Bharani, Ameen M, Abraham S, Job V et al. A double-blind, randomized, multicenter study evaluating the effects of pioglitazone in fasting Muslim subjects during Ramadan. Int J Diabetes Dev Ctries 2006; 26: 70–76.
38. Ahrén B, Schweizer A, Dejager S, Villhauer FB, Dunning BE, Foley JE. Mechanisms of action of the dipeptidyl peptidase–4 inhibitor vildagliptin in humans. Diabetes Obes Metab 2011; 13: 775–783.
39. Hanif W, Malik W, Hassanein M, Kamal A, Geransar P, Andrews C. Treatment adherence with vildagliptin compared to sulphonylurea as add-on to metformin in Muslim patients with type 2 diabetes mellitus fasting during Ramadan. Curr Med Res Opin 2013; 29: 807–811.
40. Al Sifri S, Basiounny IA, Echtay A, Al Omari M, Harman-Boehm I, Kaddaha G et al. The incidence of hypoglycaemia in Muslim patients with type 2 diabetes treated with sitagliptin or a sulphonylurea during Ramadan: a randomised trial. Int J Clin Pract 2011; 65: 1132–1140.
41. Tahrani AA, Barnett AH, Bailey CJ. SGLT inhibitors in management of diabetes. Lancet Diabetes Endocrinol 2013; 1: 140–151.
42. Abdul-Ghani MA, Norton L, Defronzo RA. Role of sodium–glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes. Endocr Rev 2011; 32: 515–531.
43. U.S. Food and Drug Administration. Drug Safety Communication: FDA warns that SGLT2 inhibitors for diabetes may result in a serious condition of too much acid in the blood [Internet], 15 May 2015. Available at http://www.fda.gov/downloads/Drugs/DrugSafety/UCM446954.pdf Last accessed 21 October 2015.
44. Erondu N, Desai M, Ways K, Meininger G. Diabetic ketoacidosis and related events in the canagliflozin Type 2 diabetes clinical program. Diabetes Care 2015; 38: 1680–1686.
45. Azar S, Echtay A, Mohamad W. Efficacy and safety of liraglutide versus sulphonylurea both in combination with metformin during Ramadan in subjects with Type 2 diabetes (LIRA-Ramadan): a randomised trial. Poster presented at the 75th Scientific Sessions of the American Diabetes Association (ADA), June 2015.
46. Mattoo V, Milicevic Z, Malone JK, Schwarzenhofer M, Ekangaki A, Levitt LK et al. Ramadan Study Group. A comparison of insulin lispro Mix25 and human insulin 30/70 in the treatment of type 2 diabetes during Ramadan. Diabetes Res Clin Pract 2003; 59: 137–143.
47. Akram J, De Verga V. Insulin lispro (Lys(B28)), Pro(B29) in the treatment of diabetes during the fasting month of Ramadan. Ramadan Study Group. Diabet Med 1999; 16: 861–866.
48. Hui E, Bravis V, Salih S, Hassanein M, Devendra D. Comparison of Humalog Mix 50 with human insulin Mix 30 in type 2 diabetes patients during Ramadan. Int J Clin Pract 2010; 64: 1095–1099.
49. Metzger BE, Lowe LP, Dyer AR, Trimble ER, Chaovarindr U, Coustan DR et al. Hyperglycemia and adverse pregnancy outcomes. N Engl J Med 2008; 358: 1991–2002.
50. White M, Bush J, Kai J, Bhopal R, Rankin J. Quitting smoking and experience of smoking cessation interventions among UK Bangladeshi and Pakistani adults: the views of community members and health professionals. J Epidemiol Commun H 2006; 60: 405–411.